---
provider: asta
model: Asta Scientific Corpus Retrieval
cached: false
start_time: '2026-05-26T23:12:20.770117'
end_time: '2026-05-26T23:12:25.325710'
duration_seconds: 4.56
template_file: templates/hypothesis_deep_research.md
template_variables:
  disease_name: Ovarian High-Grade Serous Carcinoma
  category: ''
  hypothesis_group_id: polq_pivot_resistance_model
  hypothesis_label: POLQ Pivot Resistance Model
  hypothesis_status: EMERGING
  hypothesis_yaml: "hypothesis_group_id: polq_pivot_resistance_model\nhypothesis_label:\
    \ POLQ Pivot Resistance Model\nstatus: EMERGING\ndescription: Under PARP-inhibitor\
    \ pressure, HRD HGSOC subclones rely on POLQ-mediated microhomology end\n  joining\
    \ as the dominant escape repair pathway. POLQ- mediated repair generates the microhomology-flanked\n\
    \  frameshift deletions that produce BRCA reversion alleles, restoring HRR and\
    \ producing acquired resistance.\n  Because POLQ is largely dispensable in normal\
    \ cells, allosteric stabilization or PROTAC degradation\n  of POLQ would act as\
    \ a second pivot point that selectively blocks the resistance route without incurring\n\
    \  host genotoxicity.\nevidence:\n- reference: PMID:39577422\n  supports: SUPPORT\n\
    \  evidence_source: HUMAN_CLINICAL\n  snippet: Among reversions mediated by frameshift\
    \ deletions, 60% are flanked by DNA microhomologies,\n    implicating POLQ-mediated\
    \ repair.\n  explanation: TOPARP-B clinical resistance analysis directly links\
    \ the dominant reversion signature to\n    POLQ-mediated repair, supporting POLQ\
    \ as the mutagenic resistance pivot."
provider_config:
  timeout: null
  max_retries: 3
  parameters:
    allowed_domains: []
    query_char_limit: 500
    paper_limit: 50
    snippet_limit: 20
    snippet_paper_limit: 50
    restrict_snippets_to_papers: false
    paper_fields: title,abstract,authors,year,url,venue,journal,tldr,publicationDate,citationCount,influentialCitationCount,externalIds
    publication_date_range: ''
    venues: ''
    inserted_before: ''
citation_count: 19
---

## Question

# Mechanistic Hypothesis Search

You are evaluating a specific disease mechanism hypothesis for the Disorder
Mechanisms Knowledge Base. This is not a general disease overview. Use the
hypothesis YAML below as the seed claim, then search for evidence that supports,
refutes, qualifies, or competes with this hypothesis.

## Target Disease
- **Disease Name:** Ovarian High-Grade Serous Carcinoma
- **Category:**

## Target Hypothesis
- **Hypothesis ID:** polq_pivot_resistance_model
- **Hypothesis Label:** POLQ Pivot Resistance Model
- **Status in KB:** EMERGING

## Seed Hypothesis YAML

```yaml
hypothesis_group_id: polq_pivot_resistance_model
hypothesis_label: POLQ Pivot Resistance Model
status: EMERGING
description: Under PARP-inhibitor pressure, HRD HGSOC subclones rely on POLQ-mediated microhomology end
  joining as the dominant escape repair pathway. POLQ- mediated repair generates the microhomology-flanked
  frameshift deletions that produce BRCA reversion alleles, restoring HRR and producing acquired resistance.
  Because POLQ is largely dispensable in normal cells, allosteric stabilization or PROTAC degradation
  of POLQ would act as a second pivot point that selectively blocks the resistance route without incurring
  host genotoxicity.
evidence:
- reference: PMID:39577422
  supports: SUPPORT
  evidence_source: HUMAN_CLINICAL
  snippet: Among reversions mediated by frameshift deletions, 60% are flanked by DNA microhomologies,
    implicating POLQ-mediated repair.
  explanation: TOPARP-B clinical resistance analysis directly links the dominant reversion signature to
    POLQ-mediated repair, supporting POLQ as the mutagenic resistance pivot.
```

## Research Objective

Build a focused hypothesis-search report that answers:

1. What is the strongest direct evidence for this hypothesis?
2. What evidence argues against it, fails to reproduce it, or limits its scope?
3. Which claims are established, emerging, speculative, or contradicted?
4. Which patient subtypes, stages, tissues, cell types, molecular pathways, or
   biomarkers does the hypothesis best explain?
5. Which alternative or competing mechanistic hypotheses explain the same disease
   features better or more parsimoniously?
6. What are the explicit knowledge gaps: missing causal steps, unconfirmed edges,
   contradictory evidence, unknown source-to-target links, or source/data absences?
7. What experiments, cohorts, assays, datasets, or trials would most directly
   distinguish this hypothesis from alternatives?

Use primary literature whenever possible. Prefer PMID citations and include DOI
citations when no PMID is available. Treat reviews as orientation unless they
contain directly relevant synthesized evidence that should be clearly labeled as
review-level support.

## Required Output

### Executive Judgment

Give a concise verdict on the hypothesis as of the current literature:
supported, partially supported, unresolved, weakly supported, or refuted. Explain
the reasoning and the most important caveats.

### Evidence Matrix

Create a table with one row per important evidence item:

- Citation (PMID preferred)
- Evidence type (human clinical, model organism, in vitro, computational, review)
- Supports / refutes / qualifies / competing
- Mechanistic claim tested
- Key finding
- Disease subtype or context
- Confidence and limitations

### Mechanistic Causal Chain

Describe the causal chain implied by the hypothesis from upstream trigger to
clinical manifestation. Identify where the literature is strong, where the links
are inferred, and where there are missing causal steps.

### Knowledge Gaps

Identify explicit known unknowns surfaced by the search. Treat absence of
evidence as a curation-relevant finding only when the search actually checked for
it. Include:

- Unknown or weakly supported causal steps in the hypothesis
- Unconfirmed causal graph edges that need direct perturbation or longitudinal
  evidence
- Conflicting evidence, failed replications, or incompatible subtype-specific
  findings
- Unknown mechanism of action for relevant treatments, biomarkers, or
  interventions tied to this hypothesis
- Source-level or dataset-level absences, such as no relevant GenCC, ClinGen,
  trial, omics, or cohort evidence found as of the search date

For each gap, state the scope, why it matters, what was checked, and what
evidence or experiment would resolve it.

### Alternative Models

List competing or complementary hypotheses. For each, explain whether it is an
alternative to the seed hypothesis, a downstream consequence, an upstream cause,
or a parallel mechanism.

### Discriminating Tests

Recommend concrete studies or assays that would most efficiently test this
hypothesis against alternatives. Include patient stratification, biomarkers,
sample type, model system, perturbation, and expected result where applicable.

### Curation Leads

Provide candidate updates for the KB, but label these as leads requiring curator
verification. Include:

- candidate evidence references and exact abstract snippets to verify
- candidate pathophysiology nodes or edges
- candidate ontology terms for cell types and biological processes
- candidate subtype restrictions or status changes
- candidate `knowledge_gaps` or discussion prompts for unresolved causal claims,
  conflicting evidence, or explicit source/data absences

If the provider supports artifacts, produce artifact-friendly outputs such as an
evidence matrix, mechanistic diagram, knowledge-gap table, or comparison table.
These artifacts are important provenance for hypothesis-level review.


## Output

# Asta Literature Retrieval: Mechanistic Hypothesis Search You are evaluating a specific disease mechanism hypothesis for the Disorder Mechanisms...

This report is retrieval-only and is generated directly from Asta results.

- Papers retrieved: 19
- Snippets retrieved: 20

## Relevant Papers

### [1] Gathering Evidence of Mechanisms
- Authors: Veli-Pekka Parkkinen, Christian Wallmann, Michael Wilde, B. Clarke, P. Illari et al.
- Year: 2018
- Venue: Unknown venue
- URL: https://www.semanticscholar.org/paper/06480fd932fc88915a4efb4c894a5ae4ed98452d
- DOI: 10.1007/978-3-319-94610-8_5
- Citations: 1
- Summary: Key issues include increased precision concerning the nature of the hypothesis being examined, attention to differences between the study population and the target population of the evidence assessors, and being alert for masking mechanisms, which are other mechanisms which may mask the action of the mechanism being assessed.
- Evidence snippets:
  - Snippet 1 (score: 0.589)
    > General mechanistic claim for efficacy. In formulating the general mechanistic claim for efficacy, the following questions should be addressed:
    > • What is the relevant population?
    > • What is the intervention or exposure level?
    > • What is the outcome and how is it measured? General mechanistic claim for external validity. In determining the general mechanistic claim concerning external validity, the following questions should be addressed:
    > • What is the target population? What is the study population?
    > • What is the intervention or exposure level in the target?
    > • What is the outcome and how is it measured in the target?
    > • What is the intervention or exposure level in the study?
    > • What is the outcome and how is it measured in the study?
    > It may be that existing evidence from clinical studies together with already wellestablished mechanisms is enough to establish the general mechanistic claim. In other cases, the existing evidence fails to establish causality, and it is necessary to identify and evaluate mechanistic studies. To this end, this chapter presents the following five-step strategy for gathering evidence of mechanisms:
    > 1. Identify: Identify a number of specific mechanism hypotheses. 2. Formulate: For each specific mechanism hypothesis, formulate a number of review questions. 3. Search: Use these review questions to search the literature. 4. Refine: Identify the evidence most relevant to the mechanism hypothesis by refining the results of this search. 5. Present. Present the evidence relevant to the mechanism hypothesis. This strategy is intended to help overcome some of the practical difficulties with identifying evidence of mechanisms-difficulties which may prevent appraisers from considering all the relevant evidence. Once this evidence of mechanisms has been identified, it can then be evaluated alongside the existing evidence of correlation from clinical studies, as explained in Chaps. 6 and 7.
    > The overall approach of this chapter is illustrated in Fig. 5.1. The five steps outlined above are explained in detail in the following sections.
  - Snippet 2 (score: 0.518)
    > The overall approach to gathering evidence of mechanisms of action. Each proposed mechanism of action, or partial description of proposed mechanism of action, is a specific mechanism hypothesis. But note that a specific mechanism hypothesis need not be a complete description of a mechanism.
    > Example: Specific mechanism hypotheses for determining efficacy.
    > Aspirin prevents heart disease via cyclooxygenase (COX) inhibition, and the mechanisms that underlie this prevention are established. However, aspirin also seems to reduce the incidence of some cancers. Here, the mechanisms are much less well understood. As Chan et al. (2011) write: "the mechanism of aspirin's antineoplastic effect is less clear, with substantial evidence supporting both COX-dependent and COX-independent mechanisms. Moreover, data supporting the importance of COX-dependent mechanisms are not entirely consistent concerning the relative importance of the COX-1 and COX-2 isoforms in carcinogenesis". In this quotation, the general mechanistic claim is that aspirin exhibits an antineoplastic effect. There are also a couple of more specific mechanism hypotheses, for example, that this antineoplastic effect is mediated by COX-dependent mechanisms. Evidence relating to these more specific mechanism hypotheses provides a way to determine the status of the general mechanistic claim.
    > External validity. In order to evaluate the general mechanistic claim that there is a mechanism in the target population sufficiently similar to the mechanism responsible for the correlation observed in the study population, specific mechanism hypotheses need to pertain to the mechanism of action. It is important to consider the possibility that the mechanism in the target population may contain further component mechanisms that counteract the mechanism of action in the study population and affect the extent of the correlation between the putative cause and effect. So one needs to ask, are there any masking mechanisms in the target population?
    > Example: Specific mechanism hypotheses for determining external validity.
    > According to NICE guidelines, treatment for hypertension should differ depending on ethnicity (NICE 2011). Although ACE-inhibitors have proved beneficial for hypertension in many study populations, there remains the question of whether they are the optimal treatment in some distinct target population, such as African or Caribbean populations.

### [2] A diseasome cluster-based drug repurposing of soluble guanylate cyclase activators from smooth muscle relaxation to direct neuroprotection
- Authors: F. Langhauser, A. I. Casas, V. Dao, E. Guney, Jörg Menche et al.
- Year: 2018
- Venue: NPJ Systems Biology and Applications
- URL: https://www.semanticscholar.org/paper/44d6cd1d0dd2993b9a9f6b17e3f9705fb04892b8
- DOI: 10.1038/s41540-017-0039-7
- PMID: 29423274
- PMCID: 5799370
- Citations: 61
- Influential citations: 2
- Summary: It is shown that, based on this principle, a cardio-pulmonary drug can be surprisingly repurposed for a previously not recognised application as a direct neuroprotectant, and it is found that the cyclic GMP forming soluble guanylate cyclase becomes dysfunctional upon stroke but regains catalytic activity in the presence of specific activator compounds.
- Evidence snippets:
  - Snippet 1 (score: 0.546)
    > Drug discovery and development follows a relatively uniform path from mechanistic hypothesis, preclinical disease models to clinical validation. However, in recent years, a string of major drug developments have failed due to lack of efficacy. 1 One reason for this appears to reside in our current definitions of 'disease', i.e., mostly organ-based or by an apparent phenotype or symptom and not by an underlying mechanisms. However, without a validated pathomechanism no mechanism-based drugs can be developed and, therefore, rather surrogate parameters or risk factors are treated instead. Finding a rational approach towards mechanism-based disease definitions may therefore have a tremendous impact on drug discovery and medicine in general.
    > Using a data-driven approach, disease-disease networks (diseosome) have been constructed in which diseases are linked based on common molecular or regulatory mechanisms, 2 such as shared genetic associations, 2 protein interactions 3,4 or gene-disease interactions. 5 These diseasomes exhibit local clusters of diseases whose molecular relationships are well understood, but also unexpected clusters of surprisingly heterogeneous diseases. 3 Such clustering of disease phenotypes is likely due to underlying hidden common pathomechanisms. Importantly, these common mechanism clusters may provide previously unrecognized molecular definitions of these phenotypes and at the same time targets for mechanism-based drug discovery and repurposing.
    > Here we test the clinical validity of this approach by focusing on one cluster of highly prevalent combinations of vascular, neurological and metabolic disease phenotypes with high unmet medical need. Genetic evidence points to cGMP signaling as being part of its underlying pathomechanism. 5,6 We then inquire in a non-hypothesis-based manner using disease-disease networks based on common genetic origins, common protein interactions between disease genes, shared disease symptoms and disease co-morbidity for possible drug repurposing of cGMP modulators within this cluster.

### [3] The fetal origins of adult disease: a narrative review of the epidemiological literature
- Authors: J. Skogen, S. Øverland
- Year: 2012
- Venue: JRSM Short Reports
- URL: https://www.semanticscholar.org/paper/b665dc20a1f7355f7c82e370d1e1fa3a0e2a7fce
- DOI: 10.1258/shorts.2012.012048
- PMID: 23301147
- PMCID: 3434434
- Citations: 102
- Influential citations: 4
- Summary: It is concluded that much of the research literature on the FOAD-hypothesis finds support for the hypothesis, and should be considered a major insight and constitutes a complement to a focus on genetic and more proximal factors (such as adult lifestyle) as causes of adult disease.
- Evidence snippets:
  - Snippet 1 (score: 0.529)
    > The FOAD-hypothesis has been praised as a paradigmatic shift from proximal factors to include distal factors as determinants of disease. 23 Some now argue that the empirical support for the link between an adverse intrauterine environment and later specific disease is so strong, that our focus should be to search for mechanisms. 24 thers criticize the hypothesis on a number of accounts, both methodologically and theoretically.
    > Susser and colleagues 25,26 has argued that the original hypothesis is too vaguely and broadly defined. According to them, stating that a fetus' nutritional status during gestation will influence the disease risk in adulthood, allows researchers to test a near unlimited matrix of potential nutritional measures and any later disease. Such a setting is prone to produce 'Type-I' errors. 27 Secondly, due to the general formulation of the original hypothesis it could not be readily falsified, which is crucial in scientific theory testing. 28 ather, as Paneth and Susser put it: 'example is piled on example, each somewhat consistent with hypothesis but none seriously testing it'. 26 These criticisms have been met to a certain degree by a further refinement of the basic hypothesis, 6 as well as a elaboration of the hypothesis in relation to specific diseases (such as the 'thrifty phenotype'). Additionally, there has been an increased focus on potential mechanisms underlying the proposed causal relationship, 6,11 including research based on animal models and intervention studies involving human subjects. 29 -31 Thus, through a more clear-cut formulation of the hypothesis (and disease-specific sub-hypotheses), development of a theoretical framework, identification of potential mechanisms and replication in animal models, some of the early criticism regarding the FOAD-hypothesis have been addressed. 27 he FOAD-hypothesis has also been criticized on account of how one should interpret the statistical association between anthropometric measures at birth, and outcomes in adulthood. As for any observed association, the relationship could be a result of chance, bias, confounders, or it may be a genuine causal effect. 32 any of the early criticisms of the observed association between anthropometric measures at birth and later disease concerned the lack of adjustment for important third variables. 25

### [4] A Resident’s Perspective of Ovarian Cancer
- Authors: Christopher G. Smith
- Year: 2017
- Venue: Diagnostics
- URL: https://www.semanticscholar.org/paper/e7187ce9b848d3233d797ed025fd8984fdc4cd36
- DOI: 10.3390/diagnostics7020024
- PMID: 28448435
- PMCID: 5489944
- Citations: 15
- Influential citations: 3
- Summary: It is demonstrated that regular TVUS examinations can detect ovarian cancer at early stages, and that survival is increased in those women whose ovarian cancer was detected with screening and who undergo standard treatment.
- Evidence snippets:
  - Snippet 1 (score: 0.523)
    > Historically, these cells can either be those that line the surface of the ovary (epithelial) or those that originate from the ovary as non-epithelial cancers (embryonic or extra-embryonic (germ), hormone-producing, or structural cells [sex-cord stromal]) [4][5][6][7][8].In recent years, numerous reports have proposed a unified hypothesis about the origin of high-grade serous ovarian cancer, implicating the Fallopian tubes fimbria as the point of origin [9][10][11][12][13][14][15][16][17][18].In this hypothesis, invasive or serous tubal intraepithelial carcinoma (STIC) originating in the Fallopian fimbria is responsible for seeding the ovaries and peritoneal cavity with malignant cells [19].However, STIC is not present in many high-grade serous carcinomas [20].
    > Ovarian cancer generally affects older women, the average age being 63 [21].Ovarian cancer is the eleventh most common cause of cancer among women, with a lifetime risk of one in 70 to develop disease [22].It is also the leading cause of death from gynecological malignancy.Nearly two thirds of ovarian carcinomas are diagnosed with disease located outside of the pelvis and thereby impose the consequences of advanced stage disease.Overall, the five-year survival rate for women diagnosed with ovarian cancer is 46%.When ovarian cancer spreads to distant sites, five-year survival decreases to 28%, and decreases to nearly 16% with Stage 4 disease [1].

### [5] An evolving story of the metastatic voyage of ovarian cancer cells: cellular and molecular orchestration of the adipose-rich metastatic microenvironment
- Authors: T. Motohara, K. Masuda, M. Morotti, Yiyan Zheng, Salma El-Sahhar et al.
- Year: 2018
- Venue: Oncogene
- URL: https://www.semanticscholar.org/paper/94e8742c8e77f59c6a2648bfdf0d8a9c9c928d7b
- DOI: 10.1038/s41388-018-0637-x
- PMID: 30568223
- PMCID: 6755962
- Citations: 192
- Influential citations: 4
- Summary: The biological mechanisms that regulate the highly orchestrated crosstalk between ovarian cancer cells and various cancer-associated stromal cells in the metastatic tumor microenvironment with regard to the omentum are reviewed to provide further insights into the development of novel therapeutic approaches for patients with advanced ovarian cancer.
- Evidence snippets:
  - Snippet 1 (score: 0.510)
    > cell carcinoma, and mucinous carcinoma [10]. These cancer types are inherently diverse diseases that are characterized by differences in precursor lesions, molecular mechanisms of carcinogenesis, patterns of progression and metastasis, responses to chemotherapy, and clinical outcomes [11][12][13][14]. In the early twenty-first century, a series of morphological and molecular genetic studies led researchers to propose a dualistic model of ovarian carcinogenesis that divided ovarian cancer into two groups: type I and type II [15,16]. High-grade serous carcinoma, which is a prototypical type II tumor, is the most common and extremely aggressive subtype and contributes primarily to the poor prognosis of ovarian cancer patients [5,17,18]. Because of the high metastatic potential of high-grade serous carcinoma, a large proportion of patients are diagnosed at an advanced stage with multiple intraperitoneal disseminated tumors. Furthermore, a marked predilection for the adipose-rich omentum as the site of metastasis can be observed [4,5]. Considering that most ovarian cancer-related deaths are directly attributable to the development of metastatic disease, an in-depth understanding of the cellular and molecular aspects of ovarian cancer metastasis is crucial to overcome this life-threatening disease [19][20][21].
    > Over a century ago, the English surgeon Stephen Paget proposed the "seed and soil" hypothesis, which stated that the pattern of metastasis is not random and that the development of cancer metastasis depends on the crosstalk between particular cancer cells "the seeds" and a specific organ microenvironment "the soil" [22,23]. Since then, extensive efforts have been made to evaluate the reciprocal interactions between cancer cells and tumor microenvironments, which are heterogeneously composed of different cell types, including fibroblasts, endothelial cells, adipocytes, various bone marrow-derived cells, such as myeloidderived suppressor cells, mesenchymal stem cells (MSCs), and macrophages [24,25]. Researchers have shown that a host of strom

### [6] Medical treatment of early stage and rare histological variants of epithelial ovarian cancer
- Authors: N. T. Cont, A. Ferrero, F. Peccatori, M. D'Alonzo, G. Codacci-Pisanelli et al.
- Year: 2015
- Venue: ecancermedicalscience
- URL: https://www.semanticscholar.org/paper/8270c46347a7cb0a9dfe7cc89d5900148bfdd23b
- DOI: 10.3332/ecancer.2015.584
- PMID: 26557882
- PMCID: 4631577
- Citations: 17
- Influential citations: 1
- Summary: Understanding the pathogenesis and the genetic background of each subtype of epithelial ovarian tumour may lead to a tailored therapy, maximising the benefits of specific treatments and possibly reducing the side effects.
- Evidence snippets:
  - Snippet 1 (score: 0.508)
    > It is hypothesised that type-1 ovarian tumours evolve from benign lesions, including endometriosis and borderline lesions. Actually, the same genetic mutations have been recognised in endometrioid ovarian cancer and concomitant endometriosis. Type-1 category includes low-grade serous, endometrioid, mucinous and clear-cell ovarian carcinoma [4]. On the contrary, type-2 ovarian tumours are high grade, aggressive tumours. Mutations involve different genes and it is hypothesised that these tumours originate from the fimbriae of the fallopian tubes as intraepithelial tubal carcinoma, which subsequently metastasise to the ovaries and to the peritoneal surface. Type-2 cancers include high-grade serous, high-grade endometrioid, malignant mixed mesodermal, and undifferentiated ovarian tumours. These subtypes differ not only for the genetic mutations and the precursor lesions: they show different prognosis, patterns of spread and response to chemotherapy [4].
    > Diagnosis of type-I ovarian cancer often occurs at an early stage, when the neoplasm is confined to one or both ovaries. These tumours are genetically stable: each histological subtype presents a typical molecular profile and specific cell-signalling pathways that might become a target for new therapies [5]. Type-II ovarian cancers are generally diagnosed at advanced stage and have an unstable genome. The high frequency of homologous recombination defects shown by these tumours represents a possible Achille's heel and treatment with PARP inhibitors demonstrated a significant antitumoural activity [5].
    > Although notable efforts have been made during the years, the mortality of patients with ovarian cancer remains high, particularly for those with advanced disease. Treatment guidelines do not differentiate among histology or molecular subtypes: one size still fits all and stage is the only discriminator for treatment [6,7,8].

### [7] Identification of fallopian tube microbiota and its association with ovarian cancer: a prospective study of intraoperative swab collections from 187 patients
- Authors: B. Yu, C. Liu, S. Proll, E. Mannhardt, S. Liang et al.
- Year: 2023
- Venue: medRxiv : the preprint server for health sciences
- URL: https://www.semanticscholar.org/paper/bd62ca397bfa9b0fa4eddce3c7b8780be9365ce9
- DOI: 10.1101/2023.06.28.23291999
- PMID: 37425928
- Citations: 2
- Influential citations: 1
- Summary: A clear shift in the microbiota of the OC patients when compared to the non-cancer patients is found and establishes the scientific foundation for future investigation into the role of these bacteria in the pathogenesis of ovarian cancer.
- Evidence snippets:
  - Snippet 1 (score: 0.507)
    > The American Cancer Society estimates that in 2023, about 19,710 new cases of ovarian cancer (OC) will be diagnosed and about 13,270 individuals will die from OC in the United States (1). Unlike most other cancers, the mortality rate for OC has declined only slightly in the last 40 years due to lack of early diagnostic tests and effective treatments. The 5-year survival rate for all types of OC averages 49.7%, much lower than many other cancers (2). The high mortality rate of OC is linked to a lack of understanding of ovarian carcinogenesis and precursor lesions, contributing to the failure of early detection and late-stage diagnosis. Even the cell origins of various OC subtypes have not been fully appreciated until recently, with ovarian carcinoma representing a heterogeneous collection of cancer subtypes, each with distinct origins and molecular drivers (3). The Fallopian tube epithelium is the likely origin of most high-grade serous carcinomas, the most common subtype of ovarian carcinoma. There is a critical need for innovative research to illuminate the origins and pathogenesis of this deadly cancer, thus enabling targeted approaches for early detection, treatment and prevention.
    > Based on the epidemiological data, we propose a novel hypothesis for ovarian carcinogenesis: ascending infection with some genital tract bacteria leads to inflammation in the fallopian tubes and DNA damage to cells contributing to neoplastic transformation. The evidence supporting this hypothesis includes: 1) The fallopian tubes form a conduit between the lower genital tract and the pelvic cavity (4,5). 2) Blocking the communication between the fallopian tubes and the environment, such as through tubal ligation or hysterectomy, results in lower ovarian cancer incidences (6)(7)(8). 3) Increased cellular and bacterial transit between the lower genital tract and the peritoneal cavity, as in endometriosis or pelvic inflammatory disease, is associated with increased ovarian cancer risks (9,10). 4) Inhibiting ovulation through oral contraceptives may decrease ovarian cancer risks (11)(12)(13)

### [8] Utility of compartmental models to test the competing hypotheses of pathogen evolution and human intervention
- Authors: Barsha Saha, Majid Bani-Yaghoub, C. Podder
- Year: 2026
- Venue: Frontiers in Public Health
- URL: https://www.semanticscholar.org/paper/749f3bc337708c7462f520ae5f06ceb914a49149
- DOI: 10.3389/fpubh.2025.1702428
- PMID: 41626397
- PMCID: 12853639
- Citations: 1
- Summary: A new model-based hypothesis testing (MBHT) approach, which uses compartmental models to evaluate the hypotheses in epidemiology and reveals that model-based hypothesis testing offers a powerful yet underutilized approach to uncovering drivers of viral mutation and gaining deeper insights into pathogen evolution during outbreaks.
- Evidence snippets:
  - Snippet 1 (score: 0.506)
    > Model-Based Hypothesis Testing (MBHT) is a framework that enables researchers to evaluate competing mechanistic hypotheses by integrating compartmental models with relevant data. In many settings, there is insufficient direct evidence to distinguish among hypotheses at the level of individual parameters or mechanisms. Unlike traditional hypothesis testing, which typically relies on a test statistic derived from observed data, MBHT leverages the output of a validated dynamical model that captures the underlying ecological, evolutionary, or epidemiological processes (37,38). For example, even when direct measurements of disease transmission rates or virulence are unavailable, their distributions can be inferred by fitting a compartmental model to morbidity and mortality data. These inferred parameter distributions can then be used to quantify the relative support for alternative hypotheses. In this way, MBHT enhances the specificity and interpretability of inference by comparing hypotheses through model-based simulations rather than relying solely on empirical contrasts.
    > The MBHT approach differs fundamentally from classical hypothesis testing by offering a mechanistic, model-driven framework tailored to nonlinear, time-dependent systems. Conventional statistical methods typically compare outcomes between control and treatment groups, assuming that the relevant mechanisms can be probed directly from data. In contrast, MBHT relies on model analysis and simulation to identify the best-supported hypothesis, especially when key mechanisms are only indirectly observed (39). Algorithms such as Approximate Bayesian Computation, Markov Chain Monte Carlo, and machinelearning-based emulators can be used to align model output with observed data and to assess the robustness of conclusions. This makes MBHT particularly well suited for dynamic systems such as pathogen evolution, where feedbacks between transmission, immunity, and intervention strategies create complex adaptive and co-evolutionary dynamics that may not be adequately captured by standard statistical tests. Figure 1 summarizes the typical workflow for applying MBHT to ecological and evolutionary systems or other complex dynamical settings. First, competing hypotheses are formulated on the basis of a comprehensive literature review and supplemented with data from relevant repositories. To test these hypotheses, a compartmental disease model is constructed, analyzed using standard mathematical tools, and simulated by sampling parameter values from specified prior ranges.

### [9] New Insights into the Pathogenesis of Ovarian Cancer: Oxidative Stress
- Authors: G. Saed, R. T. Morris, N. Fletcher
- Year: 2018
- Venue: Ovarian Cancer - From Pathogenesis to Treatment
- URL: https://www.semanticscholar.org/paper/6c74938095716cbd46a218acde0b4b89bd78f7ae
- DOI: 10.5772/intechopen.73860
- Summary: This chapter provides the reader with up to date most relevant findings on the role of oxidative stress in the pathogenesis and prognosis of ovarian cancer, as well as a novel mechanism of apoptosis/survival in EOC cells.
- Evidence snippets:
  - Snippet 1 (score: 0.501)
    > [11][12][13]. The persistent generation of cellular reactive oxygen species (ROS) is a consequence of many factors including exposure to carcinogens, infection, inflammation, environmental toxicants, nutrients, and mitochondrial respiration [14][15][16][17].
    > The origin and causes of ovarian tumors remains under debate. Injury to surface epithelial ovarian cells due to repeated ovulation is thought to induce tumorigenesis in these cells and is known as the "incessant ovulation hypothesis." Additionally, hormonal stimulation of the surface epithelium of the ovary has been described to initiate tumorigenesis in surface epithelial cells and is known as the "gonadotropin hypothesis." Moreover, the fallopian tube, and not the ovary, has been suggested to be the origin for most epithelial ovarian cancer [2,18,19]. Nevertheless, many cases of ovarian cancer continue to be described as de novo.
    > Histopathologic, clinical and molecular genetic profiles were successfully utilized to clearly discriminate between type I and type II ovarian tumors [19]. Accordingly, type I ovarian tumors develop from benign precursor lesions that implant on the ovary and include clear cell, endometrioid, low-grade serous carcinomas, mucinous carcinomas and malignant Brenner tumors [19]. Type II ovarian tumors develop from intraepithelial carcinomas of the fallopian tube and can then spread to involve both the ovary as well as other sites, such as high-grade serous carcinomas which comprise morphologic and molecular subtypes [19]. Additionally, high-grade endometrioid, poorly differentiated ovarian cancers, and carcinosarcomas are also classified as type II tumors.
    > Attempts to identify specific genes in ovarian tumors to help in early detection of the disease and serve as targets for improved therapy had failed to identify reproducible prognostic indicators [2,[20][21][22]. Several oncogenic mutations and pathways have been identified in ovarian cancer. Specific inherited mutations in the BRCA1 and BRCA2 genes that produce tumor

### [10] Knowledge Discovery in Databases of Proteomics by Systems Modeling in Translational Research on Pancreatic Cancer
- Authors: M. Resell, Elisabeth Pimpisa Graarud, Hanne-Line Rabben, Animesh Sharma, Lars Hagen et al.
- Year: 2025
- Venue: Proteomes
- URL: https://www.semanticscholar.org/paper/a85dc648931c1ed657e57d11de0bcbfca8a4efd9
- DOI: 10.3390/proteomes13020020
- PMID: 40559993
- PMCID: 12196815
- Citations: 1
- Summary: This systems modeling workflow can be a valuable method for KDD, facilitating knowledge discovery in translational targets in general, and in particular to PADA in this case.
- Evidence snippets:
  - Snippet 1 (score: 0.499)
    > We hypothesized that the translational gap in PDAC research arises from mismatches between research models and actual patient conditions. To address this, we aimed to develop and validate the systems modeling workflow designed to identify 'translatable targets' for PDAC. Our workflow incorporated a comprehensive range of PDAC models, including murine PDAC cells, murine normal pancreas tissue, murine PDAC spheroids, murine PDAC organoids, murine pancreatic exocrine organoids, human PDAC organoids and human PDAC tumor tissue for data collection, particularly on proteomics. Analytic methods included bioinformatics and AI/ML. With filters in each step, the knowledge on potential translational targets was discovered, which led to new hypothesis generation, test and validation (Figure 1). ). These hypotheses are subjected to 'objective filter' and then tested using one or more research models, clinical data and trials. In this study, five distinct models were employed, including murine PDAC cells, spheroids, organoids, orthotopic model, and human PDAC organoids. To address the translational gap, patientderived materials were utilized as a 'matching filter,' ensuring that the models closely align with the human disease. The datasets included in this work comprised proteomic profiles from both research models and patient samples (showed in grey scare). The data analysis in this work (showed in light-blue squares) included data mining with functional enrichment analysis and machine leaning. A 'knowledge filter', as a 'human-in-the-loop' element, was employed for interpreting data, and a 'hypothesis filter' was used for the knowledge discovery, e.g., targeted proteins and signaling pathways. The knowledge presentation in this work can lead to the validation of a hypothesis and the generation of new hypotheses.

### [11] PAX2 Expression in Low Malignant Potential Ovarian Tumors and Low-Grade Ovarian Serous Carcinomas
- Authors: C. Tung, S. Mok, Y. Tsang, Z. Zu, Huijuan Song et al.
- Year: 2009
- Venue: Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
- URL: https://www.semanticscholar.org/paper/120fdba92f33c126e0e86008300cb927c4350a14
- DOI: 10.1038/modpathol.2009.92
- PMID: 19525924
- PMCID: 2736318
- Citations: 99
- Influential citations: 8
- Summary: The presence of PAX2 expression in normal ovarian epithelia but expression in fallopian tube fimbria and ciliated epithelial inclusions would suggest the potential development of tumors of low malignant potential and of low-grade ovarian serous carcinomas from secondary Müllerian structures.
- Evidence snippets:
  - Snippet 1 (score: 0.499)
    > Ovarian cancer, a leading cause of cancer deaths among women in the United States, is estimated to affect over 20,000 women each year, with over 15,000 dying of the disease.(1) Serous carcinoma, the major histologic subtype of ovarian cancer, represents about 87% of advanced-staged cases. (2) Currently, no uniform grading system exists despite the fact that histologic grade is a significant prognostic factor in women with epithelial ovarian carcinoma.(3) Malpica et al. proposed a 2-tiered grading system for ovarian serous carcinoma based on nuclear atypia and mitotic rate and classified tumors into low-grade versus high-grade.(4) Low-grade carcinomas and ovarian serous tumors of low malignant potential are often associated together in histologic and molecular studies and are rarely linked with high-grade ovarian carcinoma. (4,5) Differences in clinical behavior further support the distinction between the two grades. Low-grade carcinomas are typically characterized by a younger patient population with longer overall survival and increased platinum chemoresistance compared to high-grade carcinomas. (6) These variations in histologic and clinical behavior have led investigators to suggest that low-grade and highgrade ovarian serous carcinomas may develop along different pathways, and tumors of lowmalignant potential may exist on a continuum with low-grade ovarian serous carcinoma.
    > The precise etiology and pathogenesis of ovarian carcinoma remains elusive despite significant research. The cell of origin is still widely unknown and debated. The most common hypothesis is that ovarian carcinomas develop from the surface epithelium or postovulatory inclusion cysts in response to trauma or prolonged exposure to hormones or other chemokines. (7)(8)(9) However, growing evidence suggests other possible etiologies, including the tubal epithelium and distal endosalpinx. (10,11) Molecular and translational studies have suggested that differences in development pathways may contribute to the clinical, histologic, and genetic differences between low-grade and high-grade ovarian serous carcinomas

### [12] SKiM-GPT: combining biomedical literature-based discovery with large language model hypothesis evaluation
- Authors: Jack Freeman, R. Millikin, Leo Xu, Ishaan Sharma, Bethany Moore et al.
- Year: 2025
- Venue: BMC Bioinformatics
- URL: https://www.semanticscholar.org/paper/ce7a6900a181708dba6ed2bf612d06b0be1d20b1
- DOI: 10.1186/s12859-025-06350-7
- PMID: 41408154
- PMCID: 12829140
- Summary: SKiM-GPT is introduced, a retrieval-augmented generation (RAG) system that combines SKiM’s co-occurrence search and retrieval with frontier LLMs to evaluate user- defined hypotheses, and achieves strong ordinal agreement with four expert biologists, demonstrating its ability to replicate expert judgment.
- Evidence snippets:
  - Snippet 1 (score: 0.490)
    > B Positive hypothesis condition. Without any provided abstracts ("No text"), when asked whether each drug "improves breast-cancer patient outcomes, " SKiM-GPT assigns positive scores (median = + 2), indicating that parametric (trained) memory is biased towards positive scores in these cases as expected ("parametric-knowledge leakage"). C Neutral hypothesis condition. Feeding synthetic abstracts that state no relationship exists between the drug and breast cancer patient outcomes increases scores for neutral hypotheses (median = + 2) for all drugs, indicating the model grounds its judgment in the supplied context rather than internal bias. D Negative hypothesis condition. Providing synthetic abstracts that refute drug efficacy results in increased scores for negative hypotheses (median = + 2). Together, panels B-D indicate that SKiM-GPT's scores mirror the sentiment of the abstracts rather than the LLM's training data SKiM-GPT correctly classified 19 of them, confirming 16 true drug-gene treatment links (positive scores) and correctly discarding three false positives (zero or negative scores). In the one case where SKiM-GPT was unable to correctly classify, the gene name SLN returned no relevant abstracts, as the abbreviation SLN can also stand for "sentinel lymph node" which is often a term associated with cancers.
    > Table 2. Assessment of SKiM-GPT's ability to remove false-positive hits in an LBD search. "Breast Cancer" was used as the A-term, a list of human genes as B-terms, and FDA-approved drugs as C-terms. The hypothesis "{C-term} treats {A-term} through its effect on {B-term}" was used to evaluate the top 20 hits ranked by p-value. For each SKiM A-B-C hit (column 1), SKiM-GPT scores the provided hypothesis from −2 (strongly refutes) to + 2 (strongly supports) after relevance filtering (column 2). Scores were classified as a true-positives (TP) or true-negatives (TN) based on current clinical or mechanistic evidence (column 3). The comments (column 4) contain context-specific notes written by human judges.

### [13] Recent Progress in the Diagnosis and Treatment of Ovarian Cancer
- Authors: D. Jelovac, D. K. Armstrong
- Year: 2011
- Venue: CA: a cancer journal for clinicians
- URL: https://www.semanticscholar.org/paper/96bac6c0748ab090fe304e3578072cf81bf6998d
- DOI: 10.3322/caac.20113
- PMID: 21521830
- PMCID: 3576854
- Citations: 788
- Influential citations: 32
- Summary: New targeted biologic agents, particularly those involved with the vascular endothelial growth factor pathway and those targeting the poly (ADP‐ribose) polymerase (PARP) enzyme, hold great promise for improving the outcome of ovarian cancer.
- Evidence snippets:
  - Snippet 1 (score: 0.486)
    > Ovarian cancer is heterogeneous disease, and it contains several histological subtypes. EOC accounts for over 90% of primary ovarian tumors and can be classified into distinct morphologic categories: serous, mucinous, endometrioid, clear cell, transitional cell (Brenner tumors), mixed, and undifferentiated type (Table 3).
    > Papillary serous histology accounts for 75% of ovarian cancers, and its histological pattern simulates the lining of the fallopian tube. High-grade, poorly differentiated tumors are the majority and are macroscopically indistinguishable from other epithelial tumors. This histologic variant is often associated with concentric rings of calcification known as psammoma bodies. Although no universal grading schema exists for ovarian serous carcinoma, a 2-tiered system (low-grade vs high-grade) has received increasing acceptance. 35,36 ][39] Studies aimed at identifying a precursor lesion within the ovary have been largely unsuccessful. Based on the observation of a high rate of tubal intraepithelial changes (TICs) in high-risk women undergoing RRSO, it has been hypothesized that many apparent ovarian or primary peritoneal carcinomas may be of fallopian tube origin. Recent studies have documented that up to 59% of high-grade pelvic (nonuterine) serous carcinomas are associated with serous TICs. This is consistent with the hypothesis that the fallopian tube is the source of a majority of these tumors. 40 2][43] Low-grade serous carcinomas and LMP serous tumors are characterized by a young age at diagnosis and a prolonged natural history. 39 The clinical behavior of LMP tumors that recur as low-grade invasive serous carcinomas appears similar to that of newly diagnosed low-grade serous carcinomas. 37 ther studies have shown that LMP tumors often coexist with low-grade serous carcinomas, and when they recur, frequently do so as low-grade serous carcinomas. 44,45

### [14] Primary ex-vivo cultures of human fallopian tube epithelium as a model for serous ovarian carcinogenesis
- Authors: Keren Levanon, V. Ng, H. Piao, Yi Zhang, Martin C. Chang et al.
- Year: 2009
- Venue: Oncogene
- URL: https://www.semanticscholar.org/paper/a30e02ca02a8859a9ed7f4650aeae4d6b1693fcf
- DOI: 10.1038/onc.2009.402
- PMID: 19935705
- PMCID: 2829112
- Citations: 224
- Influential citations: 4
- Summary: The development of a novel ex vivo primary human FT epithelium culture system that faithfully recapitulates the in vivo epithelia is reported, as shown by morphological, ultrastructural and immunophenotypic analyses.
- Evidence snippets:
  - Snippet 1 (score: 0.486)
    > Epithelial ovarian cancer (EOC) is a leading cause of mortality in developed countries, with an incidence of about 190,000 new cases diagnosed annually worldwide, and 114,000 fatalities (Jemal et al., 2008). EOCs are generally subclassified into two types based on biological behavior and histology: low-grade tumors (also known as type I tumors), which typically present at an earlier stage and have an indolent natural history, and the high-grade or type II tumors, which typically have a more disseminated and aggressive behavior (Landen et al., 2008). Serous ovarian carcinoma (SOC) is a type II tumor and the most aggressive and most prevalent histological subtype of this disease (Cannistra, 2004). The poor prognosis of SOC is a direct consequence of advanced stage disease in a majority of newly diagnosed patients, and the eventual development of resistance to currently available chemotherapy.
    > Until recently, the ovarian surface epithelium (OSE) was considered the principal cell-oforigin for both type I and type II ovarian tumors. However, models depicting the transformation of the OSE have not been consistently corroborated by pathologic observations of transitions from OSE to malignancy. Recent studies raise a compelling hypothesis that the fallopian tube (FT) may harbor a cell-of-origin, the FT secretory epithelial cell (FTSEC), for serous tumors of the ovary and peritoneum (Jarboe et al., 2008). Evidence that supports this hypothesis includes: 1) 5-10% of BRCA+ women undergoing prophylactic salpingoophorectomy will have an early lesion, termed serous tubal intraepithelial carcinoma (STIC) and approximately 80% of these early cancers are found in the distal (fimbriated) end of the FT; 2) >50% of women with stage III/IV pelvic serous cancer also have a neoplastic lesion in their FT mucosa; 3) identical TP53 mutations have been identified in early FT neoplasia and the corresponding SOC (Kindelberger et al., 2007); 4) non-neoplastic

### [15] RareAgent: Self-Evolving Reasoning for Drug Repurposing in Rare Diseases
- Authors: Lang Qin, Z. Gan, Xu Cao, Pengcheng Jiang, Yankai Jiang et al.
- Year: 2025
- Venue: ArXiv
- URL: https://www.semanticscholar.org/paper/ad0dc7cd9de3e46fb22cc025706d54dfe58331a0
- DOI: 10.48550/arXiv.2510.05764
- Summary: RareAgent is presented, a self-evolving multi-agent system that reframes this task from passive pattern recognition to active evidence-seeking reasoning, and improves the indication AUPRC by 18.1% over reasoning baselines and provides a transparent reasoning chain consistent with clinical evidence.
- Evidence snippets:
  - Snippet 1 (score: 0.485)
    > RareAgent operationalizes the scientific discovery process using a team of four AI agents with specialized roles, who collaborate on a shared whiteboard by constructing T-EGraph.
    > • Principal Investigator (PI): The strategic orchestrator. The PI does not directly manipulate evidence but sets research goals, evaluates the state of the T-EGraph, identifies knowledge gaps, issues directives to other agents, and is responsible for self-evolutionary learning loops.
    > • Explorer: The hypothesis generator. The Explorer initiates the investigation by querying the external KG using GNN to propose an initial set of plausible drug-disease hypotheses.
    > • Proponent: The constructive advocate. The Proponent's goal is to build a coherent, mechanistic case for a given hypothesis. It searches for and adds supporting evidence to the T-EGraph, aiming to form complete causal chains (e.g., Drug → Target → Pathway → Phenotype).
    > • Skeptic: The adversarial challenger. The Skeptic's role is to challenge the current hypothesis by finding counter-evidence, identifying risks, and exposing logical fallacies. It adds refuting evidence, such as off-target effects or safety concerns, to the T-EGraph.
    > The overall workflow proceeds in three phases: (1) Hypothesis Generation, where the Explorer seeds the investigation;
    > (2) Iterative Refinement, an autonomous adversarial debate where the Proponent and Skeptic build upon the T-EGraph under the PI's guidance; and (3) Self-Evolution, where the PI analyzes completed investigations to refine agent policies and distill reusable knowledge. All four agents are realized as LLM modules with role-specific policies, and the backbone is swappable and orthogonal to our contributions.

### [16] High grade serous ovarian carcinomas originate in the fallopian tube
- Authors: S. Labidi-Galy, E. Papp, Dorothy Hallberg, N. Niknafs, V. Adleff et al.
- Year: 2017
- Venue: Nature Communications
- URL: https://www.semanticscholar.org/paper/b491df3d0b6c859c6170c9c1a949e044cc7fce0e
- DOI: 10.1038/s41467-017-00962-1
- PMID: 29061967
- PMCID: 5653668
- Citations: 642
- Influential citations: 26
- Summary: Genetic aberrances in fallopian tube lesions, ovarian cancers, and metastases from HGSOC patients are analyzed and evolutionary analyses reveal that p53 signatures and STICs are precursors of ovarian carcinoma and identify a window of 7 years between development of a STIC and initiation of ovarian cancer, with metastases following rapidly thereafter.
- Evidence snippets:
  - Snippet 1 (score: 0.483)
    > High-grade serous ovarian carcinoma (HGSOC) is the most frequent type of ovarian cancer and has a poor outcome. It has been proposed that fallopian tube cancers may be precursors of HGSOC but evolutionary evidence for this hypothesis has been limited. Here, we perform whole-exome sequence and copy number analyses of laser capture microdissected fallopian tube lesions (p53 signatures, serous tubal intraepithelial carcinomas (STICs), and fallopian tube carcinomas), ovarian cancers, and metastases from nine patients. The majority of tumor-specific alterations in ovarian cancers were present in STICs, including those affecting TP53, BRCA1, BRCA2 or PTEN. Evolutionary analyses reveal that p53 signatures and STICs are precursors of ovarian carcinoma and identify a window of 7 years between development of a STIC and initiation of ovarian carcinoma, with metastases following rapidly thereafter. Our results provide insights into the etiology of ovarian cancer and have implications for prevention, early detection and therapeutic intervention of this disease. It has previously been proposed that high-grade serous ovarian carcinoma (HGSOC) may originate from the fallopian tube. Here, the authors analyze genetic aberrances in fallopian tube lesions, ovarian cancers, and metastases from HGSOC patients and establish the evolutionary origins of HGSOC in the fallopian tube.

### [17] Learning from our GWAS mistakes: from experimental design to scientific method
- Authors: Christophe Gerard Lambert, L. Black
- Year: 2012
- Venue: Biostatistics (Oxford, England)
- URL: https://www.semanticscholar.org/paper/7c92a4bffd527e9275e5dbc57e2037bc07fa93f9
- DOI: 10.1093/biostatistics/kxr055
- PMID: 22285994
- PMCID: 3297828
- Citations: 60
- Influential citations: 1
- Summary: In an era of large-scale biological research, questions are asked about the role of statistical analyses in advancing coherent theories of diseases and their mechanisms and for renewed appreciation of falsifiable hypotheses so that the authors can learn more from their best mistakes.
- Evidence snippets:
  - Snippet 1 (score: 0.482)
    > Collecting samples without specifying preliminary hypotheses leads to a frame of mind in which genetic assays are run without an experimental design that accounts explicitly for the hypotheses to be tested-in other words, not taking steps to randomize and so prevent biases in data. As with many large biological data collection efforts, GWAS are premised on an overarching hypothesis that a disease has a genetic cause, rather than many more granular hypotheses designed to challenge a causal theory of how a disease manifests. A GWAS might test a million null hypotheses that case-control status and a given genomic SNP are statistically independent over the population sample. The experiment to falsify these null hypotheses is an automated search for indications of association between genetic variants and disease status.
    > In the traditional scientific method, a hypothesis is a proposed explanation for a phenomenon, but scientists use the hypothesis to deduce additional predicted effects which, if observed, can corroborate the hypothesis but not prove it and, if not observed as predicted, can falsify the hypothesis. A single observation can falsify a traditional scientific hypothesis.
    > Such a hypothesis might describe a force or property common to all members of a population. A hypothesis of this sort must make universal claims in order to produce repeatable experiments; then a hypothesis tested by experimenting on a member of the population could be refuted for the entire population. If we abstract a hypothesis-forming process this way-"I have observed property X in a number of instances of A; I hypothesize that all other instances of A will have property X"-then the underlying premise is "All A's are effectively identical." If all A's are effectively identical, then we should accept that a corroborated or refuted hypothesis can inform us about the universe of A's. If A's are billiard balls, and we are looking at properties of how they transfer momentum on a billiard table, we would expect all instances of these A's to have the same properties.

### [18] Endocrine disruption: fact or urban legend?
- Authors: G. Nohynek, C. Borgert, D. Dietrich, K. Rozman
- Year: 2013
- Venue: Toxicology letters
- URL: https://www.semanticscholar.org/paper/a84380ac3115ab9bed7424722a2049419d87afa3
- DOI: 10.1016/j.toxlet.2013.10.022
- PMID: 24177261
- Citations: 162
- Influential citations: 4
- Summary: Overall, despite of 20 years of research a human health risk from exposure to low concentrations of exogenous chemical substances with weak hormone-like activities remains an unproven and unlikely hypothesis.
- Evidence snippets:
  - Snippet 1 (score: 0.482)
    > tested rigorously and cannot be refuted, it must be tentatively accepted that the hypothesis may be right (Taubes, 2012). On the other hand, if repeated testing fails to generate unequivocal support, the hypothesis should be viewed with scepticism. Let us put the man-made environmental disruptor hypothesis to the test: the hypothesis has now been evaluated experimentally and epidemiologically for nearly 20 years and no convincing evidence has been found of an actual decline in human fertility, and even less of a causal relation with synthetic hormonally active substances.
    > This raises another important issue: epidemiology attempts to determine the cause(s) of an established disease (Susser, 1991). Bacteria, viruses or exposure to toxic substances may cause human diseases. To illustrate this, in the 1950s, a causal relation was established for lung cancer and tobacco smoking. Indeed, lung cancer is a genuine disease with measurable frequency. Its incidence dramatically increased in the 50s, whereas cigarette smoking became increasingly popular in the preceding decades. Exposure was certain, given that tobacco smoke is directly inhaled into the lungs. Thus the hypothesis for a causal relation made biological sense and causality was confirmed by a number of subsequent investigations that involved millions of subjects unequivocally exposed to direct inhalation of tobacco smoke. But how can one determine a cause of a disease when the existence of the disease itself is uncertain? For example, the Testicular dysgenesis syndrome (TDS) is merely a hypothetical disease, in other words: nobody knows whether this disease exists or not -some experts in the field doubt whether TDS exists at all (Thorup et al., 2010). Scientifically and philosophically, the search for a hypothetical cause of a hypothetical disease makes no sense -would it not make more sense to first make sure that the disease actually exists, before spending millions on the quest of its cause? With good reason, the quest for environmental, manmade ED has rightly been titled by the European Molecular Biology Organisation as A Cause without a Disease (Breithaupt, 2004). Nevertheless, we are now witnessing the advent of a massive regulatory programme in search of a justifiable public health purpose (Gori, 2007). Finally, even when a substance is active in an in vitro or in vivo ED assay,

### [19] Identification of disease mechanisms and novel disease genes using clinical concept embeddings learned from massive amounts of biomedical data
- Authors: A. Bugrim
- Year: 2023
- Venue: bioRxiv
- URL: https://www.semanticscholar.org/paper/ee810c8e4db715b5333cf89bf7034bfcaf424245
- DOI: 10.1101/2023.04.27.538319
- Citations: 2
- Summary: Combination of disease embeddings learned from massive amounts of biomedical records with curated data on gene-disease associations can reliably reveal groups of functionally related diseases and their molecular mechanisms and predict novel gene-Disease association co-embeddings.
- Evidence snippets:
  - Snippet 1 (score: 0.481)
    > This implies the existence of an unidentified physiological or molecular link. One hypothesis that can be put forward is that high level of activity of genes involved in vascular remodeling (such as matrix metalloproteinases MMP9, MMP2) makes a person predisposed to both: developing aortic aneurisms and suffering more severe consequences as a result of pulmonary embolism. While the role of these proteins in aortic aneurisms is well documented (41,42), the evidence has also emerged that inhibition of MMP9 in laboratory animals helps to alleviate effects of pulmonary embolism (43)(44)(45)(46) providing some support for this hypothesis. Another group of diseases (cluster "B" on Fig. 4) is a set of heart conditions. Some of these, such as heart failure and cardiac arrest are downstream effects of PE and are immediate causes of mortality in PE patients. It is interesting to note that while these conditions are aligned to PE in the embedding space, overall, there is not much similarity between diseases in cluster "B" and those in cluster "C". This may reflect the fact that in general, heart conditions are attributed to many different causes, while at the same time thrombi formation leads to many problems with PE and subsequent heart failure being only one of its consequences. This can be contrasted with the observation that myocardial infarction and acute coronary syndrome, rather than being grouped with other heart conditions, form a small tightly connected cluster with coronary thrombosis (cluster "E"). This shows that clinical connection of these heart conditions to coronary thrombosis is very strong and specific.
    > Above we demonstrate that close alignment of diseases in the embedding space can result from common or related molecular or physiological mechanisms. This property of disease embeddings can be leveraged for generating hypothesis about novel molecular mechanisms of pathological conditions and for suggesting potential drug targets for their treatment. It also helps to uncover unexpected mechanistic similarities between seemingly unrelated pathologies and to guide drug repositioning based on such connections. These goals are achieved by combining disease embedding with gene-disease association data.

## Notes

- This provider combines `search_papers_by_relevance` with `snippet_search`.
- No synthesis or second-stage model call is performed.
